M

Myomo Inc
AMEX:MYO

Watchlist Manager
Myomo Inc
AMEX:MYO
Watchlist
Price: 6.42 USD Market Closed
Market Cap: 216.3m USD
Have any thoughts about
Myomo Inc?
Write Note

Myomo Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Myomo Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
M
Myomo Inc
AMEX:MYO
Capital Expenditures
-$531.6k
CAGR 3-Years
-19%
CAGR 5-Years
-62%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Capital Expenditures
-$725m
CAGR 3-Years
15%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Boston Scientific Corp
NYSE:BSX
Capital Expenditures
-$780m
CAGR 3-Years
-15%
CAGR 5-Years
-8%
CAGR 10-Years
-10%
Stryker Corp
NYSE:SYK
Capital Expenditures
-$634m
CAGR 3-Years
-9%
CAGR 5-Years
-1%
CAGR 10-Years
-11%
Abbott Laboratories
NYSE:ABT
Capital Expenditures
-$2.2B
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
-7%
Intuitive Surgical Inc
NASDAQ:ISRG
Capital Expenditures
-$1.2B
CAGR 3-Years
-67%
CAGR 5-Years
-29%
CAGR 10-Years
-33%
No Stocks Found

Myomo Inc
Glance View

Market Cap
216.3m USD
Industry
Health Care

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.

MYO Intrinsic Value
3.85 USD
Overvaluation 40%
Intrinsic Value
Price
M

See Also

What is Myomo Inc's Capital Expenditures?
Capital Expenditures
-531.6k USD

Based on the financial report for Sep 30, 2024, Myomo Inc's Capital Expenditures amounts to -531.6k USD.

What is Myomo Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-62%

Over the last year, the Capital Expenditures growth was -352%. The average annual Capital Expenditures growth rates for Myomo Inc have been -19% over the past three years , -62% over the past five years .

Back to Top